Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > high sell order

<< Previous

Bullboard Posts

Next >>

Comment by YukonJezzaon Feb 05, 2021 9:25am

161 Views

Post# 32482380

RE:high sell order

what gets me is the fact that the Sec and iiroc aren't investigating why banks lent out more shares to shorters to short than the company owned. This is highly fraudulent and and illigal. ( Naked shorting) yet no mention of this in the news.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale